灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用*

doi:10.3969/j.issn.1672-5069.2021.04.006

摘要/Abstract

摘要： 目的研究灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用。方法采用HepG2细胞构建肝癌小鼠模型,将21只造模成功的肝癌小鼠随机分为模型组、灵芝多糖(GLP)和益生菌处理组,每组7只,另选择正常小鼠7只作为对照组,给予药物处理组动物GLP或益生菌灌胃,另两组采用生理盐水灌胃,连续干预2 w。采用镜检法和变性梯度凝胶电泳法(DGGE)检测小鼠肠道菌群结构、多样性及其脂肪酸代谢产物水平。结果肝癌小鼠肠道双歧杆菌、乳酸杆菌、大肠埃希菌和肠球菌数量分别为(2.3±0.5)×10¹⁰ CFU/g、(12.2±2.2)×10⁹ CFU/g、(3.9±1.5)×10⁷ CFU/g和(5.0±1.2)×10¹⁰ CFU/g,显著高于对照组[分别为(0.94±0.18)×10¹⁰ CFU/g、(3.49±0.66)×10⁹ CFU/g、(1.12±0.11)×10⁷ CFU/g和(0.57±0.06)×10¹⁰ CFU/g,P<0.05],GLP干预组小鼠肠道上述菌群分别为(1.1±0.1)×10¹⁰ CFU/g、(6.5±1.1)×10⁹ CFU/g、(1.8±0.2)×10⁷ CFU/g和(1.5±0.1)×10¹⁰ CFU/g,均显著低于模型组(P<0.05);GLP处理组小鼠肠道菌群丰富度、多样性指数和均匀度分别为(7.2±1.1)S、(4.8±1.1)H和(1.0±0.2)E,显著高于模型组【分别为(5.7±1.2)S、(3.4±0.5)H、(0.7±0.1)E,P<0.05】;GLP干预组小鼠肠道菌群乙酸、丙酸、正丁酸和D-乳酸水平分别为(37.9±3.3)mmol/L、(3.9±0.2)mmol/L、(2.3±0.3)mmol/L和(0.2±0.0)g/L,与模型组【分别为(26.8±3.2)mmol/L、(1.8±0.4)mmol/L、(1.8±0.2)mmol/L和(0.5±0.1)g/L比,差异显著(P<0.05)。结论肝癌小鼠肠道菌群出现了失调,而应用GLP可能帮助改善机体肠道微生态紊乱状态,其意义还有待探讨。

关键词: 肝细胞癌, 灵芝多糖, 肠道菌群, 小鼠

Abstract: Objective The aim of this experimental study was to implore the regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide (GLP) in mice with HepG2 cell-induced implanted cancer. Methods The subcutaneous cancer in mice was established by HepG2 cell implantation, and 21 mice with successful implanted cancer were randomly divided into model, GLP-intervened and probiotics-intervened groups, with 7 in each. 7 normal mice were selected as control. The GLP and probiotics were administered intragastrically, while normal saline were given by gavage in model and control for 2 weeks. The diversity of intestinal floras, and fatty acid metabolites were detected by microscopy and denaturing gradient gel electrophoresis (DGGE). Results The number of Bifidobacterium, Lactobacillus, Escherichia Coli and Enterococcus in model group were(2.3±0.5)×10¹⁰ CFU/g, (12.2±2.2)×10⁹ CFU/g, (3.9±1.5)×10⁷ CFU/g and(5.0±1.2)×10¹⁰ CFU/g, all significantly higher than [(0.94±0.18)×10¹⁰ CFU/g,(3.49±0.66)×10⁹ CFU/g, (1.12±0.11)×10⁷ CFU/g and (0.57±0.06)×10¹⁰ CFU/g, respectively,P<0.05] in the control,ylajj@163.com while they were(1.1±0.1)×10¹⁰ CFU/g, (6.5±1.1)×10⁹ CFU/g, (1.8±0.2)×10⁷ CFU/g and (1.5±0.1)×10¹⁰ CFU/g in GLP-intervened group (P<0.05); the abundance, the diversity index and uniformity of intestinal floras in GLP-intervened group were (7.2±1.1)S,(4.8±1.1)H and (1.0±0.2)E, all significantly higher than [(5.7±1.2)S, (3.4±0.5)H and (0.7±0.1)E, respectively, P<0.05] in the model; the intestinal flora acetic acid, propionic acid and n-butyric acid in GLP-intervened group were (37.9±3.3)mmol/L,(3.9±0.2)mmol/L and (2.3±0.3)mmol/L, all significantly higher than [(26.8±3.2)mmol/L,(1.8±0.4)mmol/L and (1.8±0.2)mmol/L, respectively, P<0.05], while the D-lactic acid was (0.2±0.0)g/L, much lower than (0.5±0.1)g/L in the model (P<0.05). Conclusion The imbalance of intestinal floras is closely related to the carcinogenesis in mice, and the GLP administration might correct the intestinal microecological disorders, which warrants further investigation.

Key words: Hepatoma, Ganoderma lucidum plysaceharide, Intestinal flora, Mice

于雷, 孙超, 张曼旭. 灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用^*[J]. 实用肝脏病杂志, 2021, 24(4): 476-479.

Yu Lei, Sun Chao, Zhang Manxu. Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer[J]. Journal of Practical Hepatology, 2021, 24(4): 476-479.

参考文献

[1] 谢文瑞, 何兴祥. 粪菌移植与慢性肝脏疾病. 实用肝脏病杂志, 2017, 20(6):651-653.
[2] Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med, 2016, 24(67):103-17.
[3] 裴颖, 黄峰, 殷宏振, 等. 去甲斑蝥酸钠对肝癌异位移植瘤小鼠肠道微生态的影响初探. 实用肝脏病杂志, 2019, 22(4):486-489.
[4] 雍伟. 早期肠内免疫微生态营养对原发性肝癌患者术后临床疗效的影响. 实用肝脏病杂志, 2017, 20(3):328-332.
[5] Yu LX, Schwabe RF. The gut microbiome and liver cancer: mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol, 2017, 14(9):527-539.
[6] Singh V, Yeoh BS, Chassaing B, et al. Dysregulated microbial fermentation of soluble fiber induces cholestatic liver cancer. Cell, 2018, 175(3):679-694.
[7] Kladar NV, Gavari NS, Božin BN. Ganoderma: insights into anticancer effects. Eur J Cancer Prev, 2016, 25(5):462-471.
[8] Cao Y, Xu X, Liu S, et al. Ganoderma: a cancer immunotherapy review. Front Pharmacol, 2018, 25(9):1217.
[9] Ren Z, Li A, Jiang J, et al. Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68(6):1014-1023.
[10] Tripathi A, Debelius J, Brenner DA, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15(7):397-411.
[11] 朱露露, 任明, 马玉兰, 等. 高血压与肠道菌群的研究现状. 中华老年心脑血管病杂志, 2020, 22(2):207-209.
[12] Ponziani FR, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2019, 69(1):107-120.
[13] Loo TM, Kamachi F, Watanabe Y, et al. Gut microbiota promotes obesity-associated liver cancer through PGE₂-mediated suppression of antitumor immunity. Cancer Discov, 2017, 7(5):522-538.
[14] Zheng Y, Wang T, Tu X, et al. Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with hepatocellular carcinoma. J Immunother Cancer, 2019, 7(1):193.
[15] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20(2):395.
[16] Federico A, Dallio M, Caprio GG, et al. Gut microbiota and the liver. Minerva Gastroenterol Dietol, 2017, 63(4):385-398.
[17] Zhang J, Liu Y, Tang Q, et al. Polysaccharide of ganoderma and its bioactivities. Adv Exp Med Biol, 2019, 2(1181):107-134.
[18] Susilo RJK, Winarni D, Husen SA, et al. Hepatoprotective effect of crude polysaccharides extracted from ganoderma lucidum against carbon tetrachloride-induced liver injury in mice. Vet World, 2019, 12(12):1987-1991.
[19] Zhao RL, He YM. Network pharmacology analysis of the anti-cancer pharmacological mechanisms of Ganoderma lucidum extract with experimental support using Hepa1-6-bearing C57 BL/6 mice. J Ethnopharmacol, 2018, 10(210):287-295.
[20] 王婷, 周利红, 李琦, 等. 肠道菌群对肿瘤的影响及中医药调节作用研究进展. 中华中医药学刊, 2019, 37(11):2704-2707.

灵芝多糖对HepG2细胞诱导的肝癌小鼠肠道菌群及其菌群代谢功能的调节作用^*

Regulation of intestinal floras and their metabolism functions by ganoderma lucidum plysaceharide in mice with HepG2 cell-induced implanted cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	张兵, 陈瑞红, 杨威, 徐刚. 肝细胞癌患者血清HSP90α和PIVKA-Ⅱ水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2021, 24(4): 548-551.
[2]	王婷婷, 辛洋, 王娜娜. 肝细胞癌癌组织CBX7和PERK表达及其对手术治疗后患者预后的影响^*[J]. 实用肝脏病杂志, 2021, 24(4): 552-555.
[3]	于哲, 罗婧, 杨永平. 外周血单个核细胞GPSM2水平可能是肝细胞癌预后判断的新型标志物^*[J]. 实用肝脏病杂志, 2021, 24(4): 556-560.
[4]	高金龙, 王海峰, 李娜, 梁朝晖, 张文正. 自MR-T2图像勾画肝细胞癌患者放疗靶区精度研究[J]. 实用肝脏病杂志, 2021, 24(4): 565-568.
[5]	彭婕, 李弼民, 雷宇鹏. 四氯化碳诱导的肝纤维化小鼠肝组织和HSC-T6细胞NOX4基因及其蛋白表达的变化[J]. 实用肝脏病杂志, 2021, 24(3): 319-322.
[6]	王丽惠, 张佳祥, 刘双平, 张惠勇, 卢秋燕, 沈培根. 原儿茶酸对刀豆蛋白A所致的免疫性肝损伤小鼠肝组织MDA、NO、SOD和GSH-PX表达的影响[J]. 实用肝脏病杂志, 2021, 24(3): 323-326.
[7]	林列坤, 卢春生, 周应生, 郑义, 杨菊红, 邹继彬, 张仁超, 梁旭竞. 慢加急性肝衰竭小鼠肝组织组蛋白去乙酰化酶mRNA水平变化[J]. 实用肝脏病杂志, 2021, 24(3): 327-330.
[8]	都庆国, 陆建文, 王建华, 龙延滨, 薛飞. 生长抑素通过抑制内质网应激反应减轻肝纤维化小鼠肝损伤研究[J]. 实用肝脏病杂志, 2021, 24(2): 172-175.
[9]	陈少华, 吴哲, 魏志鸿, 陈鹏. 肝细胞癌患者血清癌基因和抑癌基因蛋白水平变化[J]. 实用肝脏病杂志, 2021, 24(2): 244-247.
[10]	许超, 王森钰, 罗援烨, 陈王丽, 周芸, 盛以泉, 郭满盈. 肝细胞癌患者PBMCs TLR 2/4表达和小肠细菌过度生长对TACE术后生存期的影响[J]. 实用肝脏病杂志, 2021, 24(2): 248-251.
[11]	李曼, 李静, 陈文玲, 陈永利, 王力军. 体外局部高频热疗联合放疗治疗进展期肝细胞癌患者临床疗效研究[J]. 实用肝脏病杂志, 2021, 24(2): 256-259.
[12]	王若宇, 伍玉南, 唐丹. 血浆Ki67联合miRNA-26b检测诊断肝细胞癌价值分析[J]. 实用肝脏病杂志, 2021, 24(2): 264-267.
[13]	刘奇, 郝吉庆. 免疫联合治疗肝细胞癌研究进展[J]. 实用肝脏病杂志, 2021, 24(1): 7-9.
[14]	伍畅, 田园, 刘洪岩. 酪酸梭菌活菌辅助硫普罗宁和美他多辛治疗酒精性肝病患者疗效及其对患者肠道菌群分布的影响[J]. 实用肝脏病杂志, 2021, 24(1): 75-78.
[15]	刘振, 潘光栋, 周峥, 刘强, 梁越, 黄科团, 郝树青, 杨建青. 肝细胞癌组织COPB2基因水平变化及其临床意义探讨[J]. 实用肝脏病杂志, 2021, 24(1): 115-118.